Debug Stats | ### Total Build Time: 35 ms 52.729 KB CONCEPT_NAME gt=1 ms Completed: 1 ms rowSize= 320 bytesCONCEPT_SOLR_HIT_STATS gt=0 Completed: 0 ms rowSize= 14 bytesCONCEPT_DEFINITION gt=0 Completed: 0 ms rowSize= 388 bytes- Skipping details on:
CONCEPT_SYNONYM gt=NONE 0 Completed: 0 ms rowSize= 0 bytes - Skipping details on:
CONCEPT_TEXT gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_SEMANTIC_TYPE gt=0 Completed: 0 ms rowSize= 187 bytes- Skipping details on:
CONCEPT_NAMESPACE gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_PARENTS gt=4 ms Completed: 4 ms rowSize= 1,000 bytesCONCEPT_CHILDREN gt=3 ms Completed: 3 ms rowSize= 1.403 KBCONCEPT_ANCESTRAL_ROOTS gt=1 ms Completed: 1 ms rowSize= 2.781 KBCONCEPT_RELATIONSHIPS gt=12 ms Completed: 12 ms rowSize= 13.651 KBCONCEPT_GENES gt=13 ms Completed: 13 ms rowSize= 31.869 KBCONCEPT_XREFS gt=0 Completed: 0 ms rowSize= 1.146 KBCONCEPT_ANCILLARY gt=1 ms Completed: 1 ms rowSize= 14 bytes- Reload Stats
|
Genes (25)
Species: human : 25 | |
Human | CLEC4C | 170482 | C-type lectin domain family 4, member C | INFERRED, Score=800, UMLKSK CUI: C0010633 | Human | REG4 | 83998 | regenerating islet-derived family, member 4 | INFERRED, Score=800, UMLKSK CUI: C0010633 | Human | VHL | 7428 | von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase | VHL mutation alone is insufficient for tumor formation; study shows that epididymal cystadenomas from VHL patients frequently also lack expression of the PTEN tumor suppressor and display activation of phosphatidylinositol 3-kinase pathway signaling | Human | TFF1 | 7031 | trefoil factor 1 | EXPERIMENTAL DESIGN: pS2 gene expression was investigated in benign and malignant ovary tumors and whenever possible, pS2 expression was also studied in cells collected from cystadenoma fluids. | Human | PLK1 | 5347 | polo-like kinase 1 | In this study, the expression of PLK1 and PLK3 was determined immunohistochemically in tissue specimen of normal ovaries (n=9), cystadenomas (n=17), borderline tumours (n=13) and ovarian carcinomas (n=77). PLK 1 and PLK3 expression was low in normal ovarian surface epithelium and borderline tumours, with moderately higher expression levels in cystadenomas. PLK 1 and PLK3 expression was low in normal ovarian surface epithelium and borderline tumours, with moderately higher expression levels in cystadenomas. | Human | OVGP1 | 5016 | oviductal glycoprotein 1, 120kDa | INFERRED, Score=800, UMLKSK CUI: C0010633 | Human | NME1 | 4830 | NME/NM23 nucleoside diphosphate kinase 1 | To verity the role of metastasis-related nm23 genes in carcinogenesis and progression of ovarian carcinoma, we analyzed the mRNA levels of the nm23 genes of both isoforms, -H1 and -H2, together with those of the epidermal growth factor receptor, the c-erbB-2, and the c-erbB-3 genes in 45 ovarian carcinomas and 5 benign cystadenomas. | Human | MUC5AC | 4586 | mucin 5AC, oligomeric mucus/gel-forming | In this study, we compared the expression of MUC2 and MUC5AC apomucins in 10 colonic adenocarcinomas metastatic with the ovary, 10 ovarian endometrioid carcinomas (4 primary, 6 metastatic), and 32 primary mucinous ovarian tumors (12 cystadenomas, 10 borderline tumors, and 10 cystadenocarcinomas). | Human | MCM2 | 4171 | minichromosome maintenance complex component 2 | INFERRED, Score=800, UMLKSK CUI: C0010633 | Human | LTBP1 | 4052 | latent transforming growth factor beta binding protein 1 | Semi-quantitative reverse transcription (RT)-PCR analysis showed that expression of LTBP-1 and TGF-beta 1 mRNAs was much higher in both serous and mucinous adenocarcinomas than in their benign counterparts, including serous and mucinous cystadenomas and cystadenomas of low malignant potential (LMPs). | Human | HIF1A | 3091 | hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | EXPERIMENTAL DESIGN: Expression of HIF-1alpha protein was studied by immunohistochemistry in 102 specimens of epithelial ovarian cancers, in 50 borderline tumors, and in 20 cystadenomas. | Human | FLT4 | 2324 | fms-related tyrosine kinase 4 | We assessed the presence of vascular endothelial growth factor (VEGF)-C, VEGF-D and their receptor VEGFR-3 by immunohistochemistry in 59 epithelial ovarian carcinomas, 11 borderline tumours and 20 benign cystadenomas. | Human | FIGF | 2277 | c-fos induced growth factor (vascular endothelial growth factor D) | We assessed the presence of vascular endothelial growth factor (VEGF)-C, VEGF-D and their receptor VEGFR-3 by immunohistochemistry in 59 epithelial ovarian carcinomas, 11 borderline tumours and 20 benign cystadenomas. | Human | FBLN1 | 2192 | fibulin 1 | However, in cystadenomas and borderline tumors, both fibulin-1 and ERalpha protein levels increased, in comparison with normal ovaries, suggesting an effect of estrogens in the early steps of tumorigenesis. In all lesions, excluding cystadenomas, fibulin-1 accumulation was higher in proximal stroma than in distant stroma. | Human | ETS1 | 2113 | v-ets avian erythroblastosis virus E26 oncogene homolog 1 | In the present study we found that two matrix-degrading metalloproteinases, collagenases 1 and 4 (MMPs 1 and 9), as well as the Ets-1 transcription factor are expressed at very low levels in serous benign cystadenomas, upregulated in the fibroblastic stroma, but not in the epithelium of borderline tumors and most strongly expressed in both stromal and epithelial tumor cells of serous invasive carcinomas. | Human | ELF1 | 1997 | E74-like factor 1 (ets domain transcription factor) | Elf-1 was weakly detected in some benign cystadenomas (0-5.5%). | Human | DUSP1 | 1843 | dual specificity phosphatase 1 | Immunohistochemical expression of MKP-1 protein was reduced in tissue from LMP tumors and invasive ovarian carcinomas compared to normal ovaries and cystadenomas. | Human | CTAG1B | 1485 | cancer/testis antigen 1B | NY-ESO-1 expression was seen in 19% of the serous carcinomas, whereas serous tumors of borderline malignancy and cystadenomas were negative. | Human | PLK3 | 1263 | polo-like kinase 3 | PLK 1 and PLK3 expression was low in normal ovarian surface epithelium and borderline tumours, with moderately higher expression levels in cystadenomas. In this study, the expression of PLK1 and PLK3 was determined immunohistochemically in tissue specimen of normal ovaries (n=9), cystadenomas (n=17), borderline tumours (n=13) and ovarian carcinomas (n=77). | Human | CDH13 | 1012 | cadherin 13 | LMP tumors also showed p16 (22%) and E-cadherin (17%) methylation, in addition to RARbeta (9%) and H-cadherin (4%). Three genes exhibited higher methylation frequencies in invasive tumors: RASSF1A (30% versus 0%; P = 0.0002), H-cadherin (22% versus 2%; P = 0.013), and APC (22% versus 0%; P = 0.003).CONCLUSIONS: Promoter hypermethylation is a frequent epigenetic event that occurs most commonly in invasive epithelial ovarian carcinomas. The mean methylation index was highest in invasive tumors [0.20 versus 0.065 (LMP) and 0.033 (cystadenomas); P = 0.001]. | Human | CCNB1 | 891 | cyclin B1 | METHODS: We immunohistochemically studied three representative G2-M modulators, cdc2, cyclin A and cyclin B1 in 62 pancreatic adenocarcinomas and 7 cystadenomas. | Human | BRCA2 | 675 | breast cancer 2, early onset | The study aimed to determine whether hereditary ovarian cancers that are not caused by BRCA1/BRCA2 constitutional mutations are associated with a predisposition to cystadenoma. We concluded that cystadenoma is likely to be a characteristic feature of the subgroup of families with hereditary ovarian cancers unassociated with BRCA1/BRCA2 constitutional mutations. | Human | BRAF | 673 | v-raf murine sarcoma viral oncogene homolog B | Our findings provide cogent evidence that mutations of BRAF and KRAS occur in the epithelium of cystadenomas adjacent to SBTs and strongly suggest that they are very early events in tumorigenesis, preceding the development of SBT. To address this issue, we compared the mutational status of BRAF and KRAS in both SBTs and the adjacent epithelium from cystadenomas, the presumed precursor of SBTs. | Human | CCND1 | 595 | cyclin D1 | INFERRED, Score=800, UMLKSK CUI: C0010633 | Human | AREG | 374 | amphiregulin | Amphiregulin (AR) expression was observed only in mucinous tumors (4 of 8 cystadenomas, 2 of 6 tumors of LMP, and 6 of 10 cystadenocarcinomas), but was not detected in the serous tumors or clear cell adenocarcinomas. |
|